

# Contents

<b>Preface</b> .....	5
<b>Introduction and Definitions</b> .....	7
<b>Chapter I. Nuclear Medicine, what for?</b> .....	9
I. The Case of Thyroid Cancer .....	11
II. The Diagnosis Aspect .....	12
III. The Therapeutic Aspect .....	17
1. Cancer Therapy .....	17
2. Another Therapeutic Application: Rheumatology .....	22
IV. Other Aspects in this Area .....	22
<b>Chapter II. A Little Bit of History</b> .....	25
<b>Chapter III. Some Basic Notions of Radiation</b> .....	31
I. Different Types of Radiation.....	33
II. Measurement Units and Doses.....	38
III. Radionuclides for Nuclear Medicine .....	45
1. Gamma Emitters ( $\gamma$ ) .....	46
2. Positron Emitters ( $\beta^+$ ) .....	47
3. Electron Emitters ( $\beta^-$ ) .....	48
4. Alpha Emitters ( $\alpha$ ).....	49
5. Radionuclides for Brachytherapy and External Radiotherapy.....	49
6. Other Radionuclides .....	50
Summary.....	51

<b>Chapter IV. Gamma Ray Imaging</b> .....	53
I. Nuclear Medicine Imaging Methods .....	58
1. Scintigraphy .....	60
2. The Products used in Scintigraphy .....	62
II. Imaging Tools.....	64
III. Detection of the Sentinel Node .....	66
Summary.....	68
<b>Chapter V. PET Imaging: Positron Emission Tomography</b> .....	71
I. The Imaging Principle .....	73
II. The Radiation Source .....	74
III. The Labelled Product: Fludeoxyglucose .....	75
IV. Production and Equipment .....	77
V. Applications in Cancerology .....	78
VI. Applications beyond Oncology .....	79
VII. Positron Emitters Evolution.....	80
Summary.....	81
<b>Chapter VI. Therapeutic Methods</b> .....	83
I. Metabolic Radiotherapy.....	84
II. Local Radiotherapy.....	86
III. Radioimmunotherapy .....	87
IV. Targeted Radiotherapy.....	93
V. Alphatherapy and Alpha-immunotherapy .....	94
VI. Neutron Capture Therapy.....	99
VII. Radiotherapeutic Substances.....	102
VIII. The Dose Issue .....	103
IX. Mechanism of Action – The Bystander Effect .....	104
X. The Limitations.....	106
Summary.....	108
<b>Chapter VII. The Development of Radiopharmaceuticals</b> .....	109
I. The Molecule Discovery Phase .....	111
II. Pharmacological and Preclinical Studies .....	111
III. Pharmacokinetics .....	112
IV. Toxicological Analysis .....	113
V. Phase I Clinical Studies.....	116
VI. Phase II Clinical Studies .....	117
VII. Phase III Clinical Studies.....	120
VIII. Regulatory Issues and Registration .....	123

IX. Marketing .....	125
X. Post-marketing Authorisation and Drug Monitoring.....	125
Summary.....	127
<b>Chapter VIII. The Production of Radiopharmaceuticals.....</b>	<b>129</b>
I. Definitions.....	129
II. The Principles behind Radionuclides Production .....	131
1. Particle Accelerators .....	131
2. Generators .....	133
3. Reactors.....	134
4. Fission Products.....	134
III. The Production of Vectors and Ligands .....	134
IV. The Industrial Production of Radiopharmaceuticals.....	135
V. Transport and Logistics .....	137
VI. Radiopharmacies .....	138
VII. Nuclear Medicine Centres in the World .....	140
Summary.....	145
<b>Chapter IX. Future Prospects .....</b>	<b>147</b>
I. Hybrid Imaging Tools.....	147
II. Individualised Medication .....	148
III. Orphan Diseases and Orphan Drugs .....	151
IV. Ethical and Regulatory Limitations .....	153
1. Regulation and Administration.....	153
2. Side Effects and Toxicity .....	154
3. Dosage and Indications Extensions .....	155
V. Politics and Legislation .....	156
VI. The Future .....	158
<b>Glossary.....</b>	<b>161</b>
<b>For Further Reading .....</b>	<b>169</b>